Tasdelen 2015.

Methods	A prospective cohort study of methylphenidate use
Participants	Number of participants screened: not stated Number of participants included: 22 Number of participants followed up: 17 Number of withdrawals: 5 Diagnosis of ADHD: DSM‐IV (subtype: combined (100%)) Age: mean 9.59 years old (range: 7‐12) IQ: mean: 102 (SD 10) Sex: 17 males, 5 females Methylphenidate‐naïve: 100% Ethnicity: not stated Country: Turkey Comorbidity: not stated Comedication: no Sociodemographics: not stated Inclusion criteria: ADHD DSM‐IV diagnosis CGI‐S score of ≥ 4 Exclusion criteria: Psychological, neurological or psychiatric diseases other than ADHD ADHD type other than combined Medication that influences cognitive processes or history of such medication Wechsler intelligence (WISC‐R) lower than 80 or higher than 120
Interventions	Methylphenidate type: osmotic release oral system (OROS) 36‐54 mg Mean methylphenidate dosage: 0.9 mg/kg/day Administration schedule: not stated Duration of intervention: mean 7 weeks Treatment compliance: not stated
Outcomes	Non‐serious adverse events: Several adverse events (loss of appetite, abdominal pain, irritability, tingle, headache, nausea, insomnia and tics) were observed in 12 out of 22 patients receiving OROS methylphenidate. Not stated how these adverse events were reported or measured
Notes	Sample calculation: not stated Ethics approval: yes Funding/vested interests: none Authors' affiliations: none Key conclusions of the study authors: behaviour and cognitive functionality are recovered simultaneously using OROS‐methylphenidate Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: no, all patients were newly diagnosed and methylphenidate naïve Supplemental information regarding IQ and specific adverse events received through personal email correspondence with the authors in June 2016 (Tasdelen 2016 [pers comm])